FDA Approval of Remdesivir - A Step in the Right Direction

N Engl J Med. 2020 Dec 31;383(27):2598-2600. doi: 10.1056/NEJMp2032369. Epub 2020 Dec 2.

Authors

Daniel Rubin¹, Kirk Chan-Tack¹, John Farley¹, Adam Sherwat¹

Affiliation

¹ From the Division of Biometrics IV, Office of Biostatistics (D.R.), the Division of Antivirals, Office of Infectious Diseases (K.C.-T.), and the Office of Infectious Diseases (J.F., A.S.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

PMID: 33264539
DOI: 10.1056/NEJMp2032369

No abstract available

MeSH terms

Adenosine Monophosphate / analogs & derivatives*
Adenosine Monophosphate / therapeutic use
Adolescent
Adult
Alanine / analogs & derivatives*
Alanine / therapeutic use
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
Child
Clinical Trials, Phase III as Topic
Drug Approval*
Humans
Randomized Controlled Trials as Topic
United States
United States Food and Drug Administration

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine